Medicare has delayed a program for older Americans that would’ve required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
That doesn’t mean Medicare enrollees will go without these popular weight-loss drugs. Medicare will offer GLP-1 weight-loss drugs through a bridge program from July 1, 2026, through December 31, 2027, a Centers for Medicare & Medicaid Services (CMS) spokesperson said.
The bridge program will allow enrollees in Medicare, the federal health program for adults 65 and older, to get weight-loss drugs at prices negotiated under President Donald Trump’s most favored nation agreements with Eli Lilly and Novo Nordisk.
Medicare enrollees will pay a $50 monthly copay to get the medications, according to Lilly and Nordisk officials.
The change will allow Medicare beneficiaries access to certain GLP-1 medications “outside of the Medicare Part D benefit coverage and payment flow,” CMS said.
Why Insurers Said No
The change came after multiple insurers expressed concerns about the voluntary BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) program that would’ve required Part D insurers to cover the medications. Insurers had until April 20 to commit to the program.
CVS Health, which owns Aetna, said it chose not to opt in the BALANCE program. On UnitedHealth’s earnings call on April 21, a company official cited “notable challenges and outstanding questions” about the program.
CMS announced the BALANCE program at the end of 2025 as a way for Medicare and state Medicaid plans to bypass a prohibition on covering weight-loss treatments. The BALANCE program also would’ve charged Medicare enrollees a $50 monthly copay to get the weight-loss drugs.
At the time, CMS Administrator Mehmet Oz said BALANCE would “expand access and lower prices for obesity GLP-1 medications without passing the bill to taxpayers.”
What Happens Next
CMS said the Medicaid portion of the BALANCE program will continue with applications open to states through July 31, 2026. Medicaid is jointly funded by the federal government and states, which directly manage state Medicaid programs under federal guidance.
Lilly, which sells the popular GLP-1 injectable weight-loss drug Zepbound and the weight-loss pill Foundayo, applauded CMS’s decision to launch a bridge program amid insurer uncertainty.
A Lilly spokesperson said the company “advocates the long-term vision of the BALANCE model” but added the bridge program will reach patients who can benefit for GLP-1 drugs.
A Novo spokesperson said the company would support the bridge program while working on long-term access for America’s seniors.
The extension of the bridge program through 2027 eases uncertainty around reimbursement for weight-loss drugs and blunts any near-term impact on demand, but an indefinite delay clouds long-term visibility on permanent integration into Medicare prescription drug plans, analysts said.
In the longer term, “once this obesity benefit is established, we believe it will be practically and politically difficult to roll back as we look toward 2028 and beyond,” J.P.Morgan analyst Chris Schott said, according to Reuters.
Contributing: Reuters
